Coronavirus: what is Pluristem’s placenta-based cell therapy?
Seven critically ill patients reportedly saved by experimental treatment option
Seven critically ill coronavirus patients in Israel have survived the illness after being treated with a new form of cell therapy.
The patients were given a placenta-based product provided by Pluristem, the Israeli company behind the treatment.
The Jerusalem Post reports that the patients were treated at three different Israeli medical centres for one week and were suffering from acute respiratory failure and inflammatory complications associated with Covid-19.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
All the patients survived and, according to Pluristem, four of them showed respiratory improvement, while three of them are in the advanced stages of being weaned off ventilators.
What is the treatment?
According to Pluristem, the treatment uses PLX cells, placenta-based cells that stimulate the healing of damaged tissue by triggering the body’s own regenerative mechanisms.
The company adds that PLX cells can be “grown” and administered to patients without matching them with the person’s existing tissue.
The Jerusalem Post reports that the results could be the “reversal of dangerous overactivation of the immune system.
“This would likely reduce the fatal symptoms of pneumonia and pneumonitis (general inflammation of lung tissue),” the paper adds.
In people with a dysfunctional immune system, this overstimulation of the immune system may cause what is known as a cytokine storm.
When the body is damaged, immune cells are directed to the affected area by proteins known as cytokines. In a cytokine storm, cytokines effectively send out an SOS signal that causes far too many immune cells to flood into the stricken area.
A cytokine storm sees the immune system launch all of its weapons at once, destroying the foreign invader in the body, but potentially doing irreversible damage to healthy tissue at the same time.
–––––––––––––––––––––––––––––––For a round-up of the most important stories from around the world - and a concise, refreshing and balanced take on the week’s news agenda - try The Week magazine. Start your trial subscription today –––––––––––––––––––––––––––––––
What happens next?
According to Pluristem, it now plans to apply for initiation of multinational clinical trials for treatment of complications associated with coronavirus.
“We are pleased with this initial outcome of the compassionate use programme [for use of unauthorised medicine] and committed to harnessing PLX cells for the benefit of patients and healthcare systems,” said Pluristem CEO and president, Yaky Yanay.
“Pluristem is dedicated to using its competitive advantages in large-scale manufacturing to potentially deliver PLX cells to a large number of patients in significant need.”
The company is in discussions with regulators in the United States and Europe to “define our clinical strategy for Covid-19”, Yanay added.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
'Virtual prisons': how tech could let offenders serve time at home
Under The Radar New technology offers opportunities to address the jails crisis but does it 'miss the point'?
By Chas Newkey-Burden, The Week UK Published
-
The Week contest: Airport goodbyes
Puzzles and Quizzes
By The Week US Published
-
'We shouldn't be surprised that crypto is back'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK Published
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
The world is finally feeling less negative
Under The Radar Gallup's Global Emotions Report finds moods improving for first time in a decade, but are Ukrainians really less stressed than Brits?
By Chas Newkey-Burden, The Week UK Published
-
Should masks be here to stay?
Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
By Anya Jaremko-Greenwold, The Week US Published
-
Covid might be to blame for an uptick in rare cancers
The explainer The virus may be making us more susceptible to certain cancers
By Devika Rao, The Week US Published